Staphylococcus aureus capsular polysaccharide and peptide antigens

Staphylococcus aureus capsular polysaccharides and peptide antigens are critical components targeted in the development of vaccines and immunotherapies to combat staphylococcal infections. The capsular polysaccharides, primarily serotypes 5 and 8, form a protective layer that allows the bacteria to evade opsonophagocytosis by host immune cells [Clin Microbiol Rev. 2004;17(1):218-34]. Peptide antigens, including Clumping factor A (ClfA), Manganese transport protein C (MntC), and Alpha-hemolysin (Hla), are essential for bacterial adhesion, nutrient acquisition, and the destruction of host tissues [Hum Vaccin Immunother. 2013;9(9):1891-8]. By targeting these antigens, therapeutic agents aim to induce opsonophagocytic antibodies that facilitate bacterial clearance and neutralize virulence factors [Trends Microbiol. 2012;20(9):411-2]. Despite the induction of robust immune responses, several high-profile vaccine candidates, such as StaphVAX and V710, have failed in clinical trials, sometimes even showing increased mortality in vaccinated patients who developed infections [JAMA. 2013;309(13):1368-78]. Current research focuses on multi-component vaccines, such as SA4Ag, which combine multiple polysaccharides and proteins to provide broader protection against the diverse array of S. aureus strains [Vaccine. 2017;35(35):4589-4596].

Other names

Staphylococcus aureus surface antigensS. aureus capsular polysaccharidesCP5 and CP8Staphylococcal vaccine antigensType 5 and Type 8 capsular polysaccharides

Induction of opsonophagocytic antibodies to facilitate bacterial killing by neutrophils and neutralization of staphylococcal toxins and adhesion proteins.